Before a new medical treatment can be marketed, manufacturers must show, through adequate and well-controlled clinical studies, that it is safe and effective.
Participation in clinical research trials enables our physicians to gain insight and experience in many areas of leading-edge technology and pharmaceutical development. Our contribution to significant advances in the area of genitourinary research is in keeping with our goal to bring the newest and most advanced treatments and procedures to our patients.
Research trials at Urology of Indiana are conducted with the highest level of honesty and integrity. While contributions to a patient’s health and well-being are important, patient safety and privacy are our priorities. We enroll qualified individuals in studies including but not limited to the following categories:
- Urinary Incontinence
- Impotence or Erectile Dysfunction
- Prostate Disorders
- Benign Prostate Hyperplasia (BPH)
- Stress Urinary Incontinence
- Over Active Bladder
- Complicated Urinary Tract Infection
- Acute Urinary Retention
We are currently conducting the following clinical trials:
A randomized, multi-center, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and safety of 2 doses of AQX-1125 in subjects with Interstitial Cystitis/Bladder Pain Syndrome.
A randomized, assessor-blind, controlled trial comparing the occurrence of major adverse cardiovascular events in patients with Cardiovascular Disease Receiving Degarelix or Leuprolide. Free ADT and Imaging for 1 year.
A phase 4 double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and tolerability of Mirabegron with Overactive Bladder symptoms while taking Tamsulosin Hydrochloride for lower urinary tract symptoms due to BPH.
Arches Metastatic Hormone Sensitive
A phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Enzalutamide Plus ADT versus Placebo Plus ADT in patients with Metastatic Hormone Sensitive Prostate Cancer.
ENACT Active Surveillance
A randomized study of Enzalutamide in patients with Localized Prostate Cancer Undergoing Active Surveillance.
For more information, please call Melissa at 317-893-1513 or Kim at 317-893-1511 in our Clinical Research Department.